Best deals to access real time data! |
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
VAT not included
|
|
After Hours Last Trade |
Last: $ 58.92 ▲ 0.09 (0.15%) | |
| Company Name | Stock Ticker Symbol | Market | Type | ISIN | Company Description |
|---|---|---|---|---|---|
| Merck & Company (New) | MRK | NYSE | Ordinary Share |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| +0.19 | +0.32% | 58.83 | 59.27 | 58.66 | 58.86 | 58.64 | 20:00:00 |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 48,961 | 9,646,889 | $ 58.8928 | $ 568.13M | 10.07M | 52.83 - 66.41 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:58:21 | formt | 147 | $58.92 | USD |
| Industry Sector |
|---|
| Drug Manufacturers - Major |
Merck & Company (New) Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 158.41B | 2.69B | $ 2.39B | 0.88 | 66.60 | 2.69B |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ 1.92 | 3.26% | 03/14/2018 | 203.03k | 77.90% |
Merck & Company (New) News
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) • Tue Apr 17, 2018 5:57 PM (5 days ago)
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) • Tue Apr 17, 2018 5:56 PM (5 days ago)
Merck Announces First Phase Three Studies for PCV-15 (V114) Its Investigational Pneumococcal Disease Vaccine Business Wire • Tue Apr 17, 2018 8:30 AM (5 days ago)
New Drug Combinations Improve Survival in Lung Cancer Dow Jones News • Mon Apr 16, 2018 9:59 AM (6 days ago)
Merck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed (ALIMTA®) & Platinum Chemotherapy Reduced the Risk of Death by Half Com... Business Wire • Mon Apr 16, 2018 9:30 AM (6 days ago)
Merck Bets Big on Cancer Drug -- WSJ Dow Jones News • Mon Apr 16, 2018 3:02 AM (6 days ago)
Updated Overall Survival Data for LYNPARZA® (olaparib) in gBRCA-mutated HER2-Negative Metastatic Breast Cancer Presented at ... Business Wire • Sun Apr 15, 2018 4:50 PM (7 days ago)
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MRK Price Data
| Period † | Open | High | Low | VWAP | Min Vol | Max Vol | Avg. Daily Vol [m] | Change | % |
|---|---|---|---|---|---|---|---|---|---|
| 1 Week | 57.08 | 59.96 | 56.64 | 58.6343 | 8M | 22M | 13M | 1.75 | 3.07% |
| 1 Month | 54.32 | 59.96 | 52.83 | 55.8644 | 8M | 23M | 12M | 4.51 | 8.30% |
| 3 Months | 61.49 | 62.14 | 52.83 | 55.7846 | 6M | 31M | 12M | -2.66 | -4.33% |
| 6 Months | 63.85 | 64.52 | 52.83 | 56.6055 | 4M | 48M | 12M | -5.02 | -7.86% |
| 1 Year | 62.36 | 66.41 | 52.83 | 59.4276 | 3M | 48M | 10M | -3.53 | -5.66% |
| 3 Years | 57.91 | 66.8 | 45.69 | 58.1387 | 3M | 69M | 9M | 0.92 | 1.59% |
| 5 Years | 47.27 | 66.8 | 44.6 | 55.9333 | 3M | 69M | 10M | 11.56 | 24.46% |
Merck & Company (New) Description
| Merck & Co Inc is a global health care company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. |
